Clinical trials: Diffuse Parenchymal Lung Diseases
Transbronchial Cryobiopsy, Freezing Time
The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Different Freezing Time in the Diffuse Parenchymal Lung Diseases
Transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
- Conditions
- Transbronchial Cryobiopsy, Freezing Time, Diagnostic Yield, Safety
- Trial name
- NCT03927235
- Testing
- Transbronchial Cryobiopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Idiopathic Pulmonary Fibrosis
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly…
- Trial name
- INSIGHTS-IPF (NCT01695408)
- Where
- 5 sites in Germany
- Volunteers
- 1,232 people
- Sponsor
- Technische Universität Dresden
Idiopathic Pulmonary Fibrosis
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
- Trial name
- NCT04720443
- Testing
- NIP292 tablet, NIP292 tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- The National Institutes of Pharmaceutical R&D Co. Ltd, China
Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
- Trial name
- NCT01732211
- Testing
- PD 0360324, Normal Saline for injection
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05671835
- Testing
- TTI-101
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Interstitial Lung Disease (ILD)
Non-Invasive Hemodynamic Monitoring of MV ILD Patients With ARF
Non-invasive hemodynamic monitoring of interstitial lung disease (ILD) patients admitted to respiratory ICU with acute respiratory failure and differentiate according to different modes of mechanical ventilation.
- Trial name
- NCT06927089
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Post COVID-19 Diffuse Lung Disease
Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia.
- Trial name
- COLDSTER (NCT04657484)
- Testing
- Medium dose prednisolone, Low dose prednisolone
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
COVID-19, Pulmonary Fibrosis
Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands
To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19…
- Trial name
- HOMECOMIN' (NCT04488562)
- Where
- 3 sites in Netherlands
- Volunteers
- 133 people
- Sponsor
- Erasmus Medical Center
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Families-At-risk for Interstitial Lung Disease Study
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia.
- Trial name
- FAR-ILD (NCT03641742)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Columbia University
Pulmonary Fibrosis
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan.
- Trial name
- NCT03242759
- Testing
- nintedanib, pirfenidone
- Where
- 10 sites in Taiwan
- Volunteers
- 101 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA1 (NCT03711162)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Australia and 13 more
- Volunteers
- 525 people
- Sponsor
- Lakefront Biotherapeutics NV
Liver Fibrosis, Pulmonary Fibrosis
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.
- Conditions
- Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
- Trial name
- NCT05180162
- Testing
- 68Ga-FAP-2286, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Hope
Idiopathic Pulmonary Fibrosis
PROOF-Registry New and Extended Belgium -Luxembourg
A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting.
- Trial name
- PROOF-NEXT (NCT03732859)
- Where
- 9 sites in Belgium, Luxembourg
- Volunteers
- 575 people
- Sponsor
- Belgian Thoracic Society
Systemic Sclerosis
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this…
- Trial name
- NCT07047690
- Testing
- Nemolizumab
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Langerhans Cell Histiocytosis
Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
Pulmonary Langerhans Histiocytosis Cells (PLCH) is characterized by infiltration of Langerhans cells and formation of loose granulomas with lymphocytic infiltrate and formation of nodular and cystic lesions on chest CT, and is…
- Trial name
- NCT02665546
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- InCor Heart Institute
Pulmonary Fibrosis, Interstitial Lung Disease
The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19
Up to a third of patients who recovered from SARS coronavirus (SARS-CoV) had a 20% decline in lung function with a long term reduction in exercise capacity and SF-36 health status a year after infection.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Covid19
- Trial name
- MONACO (NCT04805086)
- Testing
- MON002
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Langerhans Cell Histiocytosis
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
Langerhans cell histiocytosis (LCH) is a disease caused by clonal expansion, proliferation, and dissemination of cells that are phenotypically close to Langerhans cells in different tissues and organs.
- Trial name
- NCT03585686
- Testing
- Vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Lung Neoplasm, Lung Diseases, Interstitial
Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications
Background: Respiratory endoscopy comprises flexible bronchoscopy and medical thoracoscopy. The diagnostic yield, technical factors and complications for all patient sub-populations is still not clearly defined.
- Conditions
- Lung Neoplasm, Lung Diseases, Interstitial, Respiratory Tract Infections, Pleural Effusions
- Trial name
- NCT01374542
- Testing
- Respiratory endoscopy
- Where
- Singapore
- Volunteers
- 4,000 people
- Sponsor
- Singapore General Hospital
Pulmonary Fibrosis, Unspecified
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-PRGD2 in lung injury (LI) and pulmonary fibrosis (PF) patients.
- Trial name
- NCT02511197
- Testing
- 68Ga-NOTA-PRGD2, PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.